Glucose-6-phosphate dehydrogenase (G6PD). Response of the human erythrocyte and another cells to the decrease in their activity

Javier Fernando Bonilla, Magna Carolina Sánchez, Lilian Chuaire

Resultado de la investigación: Contribución a RevistaArtículo

7 Citas (Scopus)

Resumen

Glucose-6-phosphate dehydrogenase is the first enzyme in the pentose phosphate pathway and the main intracellular source of reduced nicotidamineadenine nucleotidephosphate (NADPH), involved in diverse physiological processes such as antioxidant defense, (for instance in the erythrocyte) endothelial growth modulation, erithropoyesis, vascularization and phagocitosis, G6PDH deficiency is the most common X-chromosome-linked enzymopathy in human beings. Although it is present in any type cell, its absolute deficiency is incompatible with life. According to WHO, 400 million people are affected by G6PD deficiency in the world but in Colombia, the severe form prevalence is about 3% to 7%. There are no data related to slight and moderate alterations, that also have clinical effects. This paper reviews some G6PD biomolecular aspects, its classification according to activity and electrophoretic mobility, as well as some main clinical aspects related to its activity alteration. © 2007 Corporación Editora Médica del Valle.
Idioma originalEnglish (US)
Páginas (desde-hasta)68-75
Número de páginas8
PublicaciónColombia Medica
EstadoPublished - ene 1 2007

Huella dactilar

Glucosephosphate Dehydrogenase
Erythrocytes
Physiological Phenomena
Glucosephosphate Dehydrogenase Deficiency
Pentose Phosphate Pathway
Colombia
X Chromosome
Antioxidants
Enzymes
Growth

Citar esto

Bonilla, Javier Fernando ; Sánchez, Magna Carolina ; Chuaire, Lilian. / Glucose-6-phosphate dehydrogenase (G6PD). Response of the human erythrocyte and another cells to the decrease in their activity. En: Colombia Medica. 2007 ; pp. 68-75.
@article{e003bcb4692f41f1bd0400de3d9c4660,
title = "Glucose-6-phosphate dehydrogenase (G6PD). Response of the human erythrocyte and another cells to the decrease in their activity",
abstract = "Glucose-6-phosphate dehydrogenase is the first enzyme in the pentose phosphate pathway and the main intracellular source of reduced nicotidamineadenine nucleotidephosphate (NADPH), involved in diverse physiological processes such as antioxidant defense, (for instance in the erythrocyte) endothelial growth modulation, erithropoyesis, vascularization and phagocitosis, G6PDH deficiency is the most common X-chromosome-linked enzymopathy in human beings. Although it is present in any type cell, its absolute deficiency is incompatible with life. According to WHO, 400 million people are affected by G6PD deficiency in the world but in Colombia, the severe form prevalence is about 3{\%} to 7{\%}. There are no data related to slight and moderate alterations, that also have clinical effects. This paper reviews some G6PD biomolecular aspects, its classification according to activity and electrophoretic mobility, as well as some main clinical aspects related to its activity alteration. {\circledC} 2007 Corporaci{\'o}n Editora M{\'e}dica del Valle.",
author = "Bonilla, {Javier Fernando} and S{\'a}nchez, {Magna Carolina} and Lilian Chuaire",
year = "2007",
month = "1",
day = "1",
language = "English (US)",
pages = "68--75",
journal = "Colombia Medica",
issn = "0120-8322",
publisher = "Universidad del Valle",

}

Glucose-6-phosphate dehydrogenase (G6PD). Response of the human erythrocyte and another cells to the decrease in their activity. / Bonilla, Javier Fernando; Sánchez, Magna Carolina; Chuaire, Lilian.

En: Colombia Medica, 01.01.2007, p. 68-75.

Resultado de la investigación: Contribución a RevistaArtículo

TY - JOUR

T1 - Glucose-6-phosphate dehydrogenase (G6PD). Response of the human erythrocyte and another cells to the decrease in their activity

AU - Bonilla, Javier Fernando

AU - Sánchez, Magna Carolina

AU - Chuaire, Lilian

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Glucose-6-phosphate dehydrogenase is the first enzyme in the pentose phosphate pathway and the main intracellular source of reduced nicotidamineadenine nucleotidephosphate (NADPH), involved in diverse physiological processes such as antioxidant defense, (for instance in the erythrocyte) endothelial growth modulation, erithropoyesis, vascularization and phagocitosis, G6PDH deficiency is the most common X-chromosome-linked enzymopathy in human beings. Although it is present in any type cell, its absolute deficiency is incompatible with life. According to WHO, 400 million people are affected by G6PD deficiency in the world but in Colombia, the severe form prevalence is about 3% to 7%. There are no data related to slight and moderate alterations, that also have clinical effects. This paper reviews some G6PD biomolecular aspects, its classification according to activity and electrophoretic mobility, as well as some main clinical aspects related to its activity alteration. © 2007 Corporación Editora Médica del Valle.

AB - Glucose-6-phosphate dehydrogenase is the first enzyme in the pentose phosphate pathway and the main intracellular source of reduced nicotidamineadenine nucleotidephosphate (NADPH), involved in diverse physiological processes such as antioxidant defense, (for instance in the erythrocyte) endothelial growth modulation, erithropoyesis, vascularization and phagocitosis, G6PDH deficiency is the most common X-chromosome-linked enzymopathy in human beings. Although it is present in any type cell, its absolute deficiency is incompatible with life. According to WHO, 400 million people are affected by G6PD deficiency in the world but in Colombia, the severe form prevalence is about 3% to 7%. There are no data related to slight and moderate alterations, that also have clinical effects. This paper reviews some G6PD biomolecular aspects, its classification according to activity and electrophoretic mobility, as well as some main clinical aspects related to its activity alteration. © 2007 Corporación Editora Médica del Valle.

M3 - Article

SP - 68

EP - 75

JO - Colombia Medica

JF - Colombia Medica

SN - 0120-8322

ER -